ProQR Therapeutics (PRQR) Long-Term Deferred Tax (2022 - 2025)

ProQR Therapeutics' Long-Term Deferred Tax history runs 4 years deep, the most recent figure standing at $3.3 million for Q4 2025.

• In Q4 2025, Long-Term Deferred Tax fell 4.37% year-over-year to $3.3 million; the TTM figure through Dec 2025 stood at $3.3 million (down 4.37% YoY), while the FY2025 annual figure was $3.3 million, down 4.37% from the prior year.
• Long-Term Deferred Tax came in at $3.3 million for Q4 2025 at ProQR Therapeutics, down from $3.5 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $4.3 million in Q4 2023 to a low of $3.3 million in Q4 2025.
• A 4-year average of $3.8 million and a median of $3.7 million in 2022 frame the typical range for Long-Term Deferred Tax.
• Across the five-year window, Long-Term Deferred Tax advanced 7.13% in 2023 and decreased 18.73% in 2024, its largest moves.
• ProQR Therapeutics' Long-Term Deferred Tax stood at $4.0 million in 2022, then advanced by 7.13% to $4.3 million in 2023, then slipped by 18.73% to $3.5 million in 2024, then retreated by 4.37% to $3.3 million in 2025.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $3.3 million, $3.5 million, and $4.3 million for Q4 2025, Q4 2024, and Q4 2023 respectively.

Peer Comparison